In the Lab
MSK investigators report exciting results for a new molecule that can block 16 different mutated forms of the KRAS protein. In the lab, the compound was effective against many cancer cell lines and in mouse models of lung cancer and colorectal cancer.
Finding
A paper from MSK researchers reports that resistance to sotorasib, a new targeted drug for lung cancer, can be caused by many different molecular changes.
In the Lab
Researchers have taken a closer look at what a protein called KRAS does in normal cells and how certain KRAS mutations lead to for cancer growth.
Feature
Read how a clinical trial is changing the outlook for some people with lung cancer.
In the Clinic
The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.
In the Lab
Recently developed targeted drugs used to treat lung cancer are only partially effective. Scientists now know why.
In the Lab
Scientists are learning how tumors develop resistance to drugs — and what can be done about it.
In the Lab
Researchers are developing uses for a drug that could benefit many people with lung cancer.
